Randomized trial · people
Semaglutide 2.4 mg: 9.6% weight loss at 68 weeks in STEP 2
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In people with type 2 diabetes, weekly semaglutide 2.4 mg led to more weight loss than placebo over 68 weeks, and stomach and gut side effects were more common on the drug.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 1210
- Published
- 2021
- Journal
- Lancet
What they tested
Does weekly semaglutide 2.4 mg help adults with overweight or obesity and type 2 diabetes lose more weight than placebo, and how does it compare on safety with the 1.0 mg dose?
How the study was done
A randomized, double-blind, placebo-controlled phase 3 trial in 1210 adults with a BMI (body-mass index, weight relative to height) of at least 27 kg/m2 and type 2 diabetes, run at 149 clinics in 12 countries. Participants got a weekly shot of semaglutide 2.4 mg, semaglutide 1.0 mg or placebo (a dummy shot) for 68 weeks, and everyone also followed a lifestyle program.

Model. Individual results vary.
What they found
By week 68, the 2.4 mg arm had lost an estimated 9.6% of body weight versus 3.4% for placebo, a gap of 6.2 percentage points. A 5% or greater weight drop was reached by 68.8% of the 2.4 mg arm and 28.5% of the placebo arm. Any adverse event was logged in 87.6% of the 2.4 mg arm, 81.8% of the 1.0 mg arm and 76.9% of the placebo arm. Digestive complaints, which were largely mild or moderate, showed up in 63.5% of the 2.4 mg arm, 57.5% of the 1.0 mg arm and 34.3% of the placebo arm.
What it doesn’t show
The trial included only adults with type 2 diabetes and a BMI of at least 27, all of whom also followed a lifestyle program, and it ran for 68 weeks, so it doesn't show what happens over a longer time. It was funded by Novo Nordisk.
The paper
Davies et al. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021.
The compound
More studies on Semaglutide
- Semaglutide: 11.85% more weight loss than placebo without diabetesMeta-analysis · people · 2022
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1Randomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.